A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. Observation, which is watching to see if cancer grows or

Trial Details

NCT ID
NCT07776691
Phase
PHASE3
Sponsor
Merck Sharp & Dohme LLC
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • R-DXd
  • Bevacizumab
Locations (sample)
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Burlington, Massachusetts, United States|42.50482,-71.19561
  • Eugene, Oregon, United States|44.05207,-123.08675
  • Amarillo, Texas, United States|35.222,-101.8313
  • Austin, Texas, United States|30.26715,-97.74306

Key Eligibility Criteria

  • The main inclusion criteria include but are not limited to the following:
  • Has a new, histologically confirmed diagnosis of International Federation of Gynecology and Obstetrics (FIGO) Stage III or Stage IV epithelial ovar…
  • Has undergone primary debulking surgery (PDS) or interval debulking surgery (IDS)
  • Has completed first-line (1L) platinum-based chemotherapy, with a response of stable disease, partial response, complete response or no evidence of…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →